“…As vaccine excipient, HPV L1 gene DNA fragments of all four genotypes, namely HPV-16, -18, -11 and -6, are expected to be present in any vaccine lot. However, previous studies have shown that only the L1 gene DNA of HPV-11 or HPV-18, or a combination of both was successfully amplified by a pair of degenerate consensus GP6/MY11 PCR primers [9], and that specially modified non-degenerate GP6/MY11 primers were needed to amplify the HPV-16 L1 gene DNA fragments bound to the insoluble fraction of the vaccine [26], indicating conformational changes taking place when naked HPV DNA is bound to the AAHS adjuvant during vaccine formulation. The topological conformational changes in the bound DNA may be genotype-related.…”